Bristol Myers Squibb stock trades in the mid-$60s as 2026 earnings guidance anchors valuation

Bristol Myers Squibb Inc. (ISIN US0897961004) stock recently changed hands in the mid-$60s, with a real-time quote of $67.28 recorded at 4:00 p.m. ET on August 24, 2026 per a market-data overview that also showed the same price in after-hours indications. At that level the shares are trading close to their 52-week high and reflect a year-to-date total return approaching 29 percent, underpinned by steady earnings and dividend support.

Guidance and consensus frame 2026 earnings picture

Recent reporting on Bristol Myers Squibb highlights that the company has set formal fiscal 2026 non-GAAP earnings guidance in a range of $6.75 to $7.00 per share, providing investors with a clearer view of the expected profit trajectory over the current year. This internal guidance band sits above some externally discussed scenario ranges that referenced non-GAAP EPS levels in the low to mid-$6 area, signaling management confidence in the earnings power of the portfolio. At the same time, coverage summarizing multiple research reports notes that the current analyst consensus for fiscal 2026 earnings stands at $6.95 per share, placing expectations in the upper half of the company’s guidance corridor and indicating that most analysts see delivery toward the higher end of the range as plausible.

The alignment between Bristol Myers Squibb’s 2026 guidance and the $6.95 consensus EPS estimate also feeds directly into valuation metrics. One sector-focused overview points out that, based on non-GAAP EPS projections around the low- to mid-$6 range for 2026, the stock is trading close to 11 times forward earnings at current share prices in the high-$60s. For a large-cap biopharmaceutical group with a diversified portfolio and recurring cash flows, that low-teens multiple is often viewed as a reasonable valuation, especially when paired with a dividend yield in the upper-3-percent area supported by a $0.63 quarterly payout.

Analyst targets cluster around current price

Alongside earnings guidance, analyst opinion provides another anchor for Bristol Myers Squibb’s stock. A forecast overview based on the research of 25 equity analysts shows an average 12-month price target of $66.06 for the shares, with individual targets spanning a high of $75.00 and a low of $40.00. With the stock trading in the $67 range as of August 24, 2026, the current market price sits only modestly above that $66.06 average objective, suggesting limited implied upside but also no sharp disconnect between Wall Street valuation models and trading levels. In percentage terms, the consensus target is described as implying around 1.5 percent downside from a reference price close to $67, which places the shares near the central point of those valuation scenarios rather than at an extreme.

Coverage aggregating different rating actions describes Bristol Myers Squibb’s overall recommendation profile as a “Moderate Buy”, derived from a mix of Strong Buy, Buy, Hold and a small number of Sell ratings. That blended stance underscores that while some analysts see more pronounced upside tied to pipeline execution and cash generation, others are more cautious on growth and competitive pressures, resulting in a balanced but gently positive view. For investors, the key numerical takeaway is that the average price target of $66.06 lies only slightly below the prevailing share price around $67, so the valuation debate now hinges less on a large gap to targets and more on whether earnings, cash flows and pipeline developments can justify a re-rating toward the upper end of the $40 to $75 target range.

Market performance, dividend and valuation context

From a market-performance perspective, a recent quote snapshot for Bristol Myers Squibb highlighted the stock at $67.28 at 4:00 p.m. ET on August 24, 2026, with no change indicated in subsequent after-hours trading. The same overview noted that the shares are currently trading in the $67 area, close to their one-year high and well above the one-year low, and that the year-to-date total return stands at 28.95 percent as of August 24, 2026. That near-29-percent gain compares favorably with broader equity benchmarks and points to renewed investor interest over 2026, particularly in the context of a defensive healthcare sector where such performance is not always driven by rapid revenue expansion but by consistent profitability and shareholder returns.

The dividend profile adds another element to the investment case. Data drawn from recent summaries mention a dividend yield around 3.8 percent for Bristol Myers Squibb, based on a quarterly dividend payment of $0.63 per share and the prevailing share price in the mid-$60s. Annualizing the dividend to $2.52 per share and comparing it with the $6.95 fiscal 2026 EPS consensus suggests a payout ratio in the area of 36 percent, which is generally regarded as sustainable for a mature biopharma group with thick margins and strong cash conversion. Combined with the forward price-to-earnings multiple of close to 11, that yield and payout ratio frame Bristol Myers Squibb as a stock where investors receive a meaningful portion of returns in cash while still retaining exposure to potential capital appreciation if the pipeline and core franchises perform well.

Relative to the analyst target framework, the year-to-date price move also stands out. With the stock delivering a 28.95 percent total return through August 24, 2026 and now trading slightly above the $66.06 average target, much of the easy catch-up to consensus appears to have taken place. The question for market participants becomes whether fresh catalysts, such as incremental data on key drugs or portfolio optimization steps, can move the consensus band higher and justify the stock exploring or exceeding the $75 upper target, or whether the current valuation near 11 times forward earnings and a near-4-percent dividend yield will cap further multiple expansion.

Representative product: oncology franchise

Within Bristol Myers Squibb’s broad portfolio, its oncology franchise remains a central pillar of the business model and a major contributor to the earnings guidance described for 2026. Flagship cancer medicines provide sizable revenue streams that underpin the projected non-GAAP EPS range of $6.75 to $7.00 per share, and ongoing label expansions and combination-therapy studies are aimed at sustaining those cash flows over the medium term. For investors interpreting the 2026 guidance and the $6.95 consensus EPS estimate, the performance and competitive positioning of these oncology products play a large role in whether the company can meet or exceed the upper end of its earnings corridor, making the franchise a practical example of how the product mix ties back to stock valuation.

Shares trade close to recent highs with steady cash returns

Bristol Myers Squibb stock is listed on the New York Stock Exchange under the ticker BMY, with trading denominated in USD and the most recent complete session snapshot showing a price of $67.28 as of August 24, 2026 at 4:00 p.m. ET. At that level the company’s market value is reported at $136.89 billion, and the shares are described as trading close to their one-year high with a year-to-date total return of 28.95 percent and a dividend yield of 3.8 percent backed by a quarterly payout of $0.63 per share. For retail investors, the combination of a forward earnings multiple near 11 based on a $6.95 consensus EPS for 2026 and a mid-single-digit cash yield means Bristol Myers Squibb stock currently offers a blend of income and moderate growth exposure without relying on aggressive valuation assumptions.

Fact box

Company: Bristol Myers Squibb Inc.

ISIN: US0897961004

Ticker: BMY

Exchange: NYSE

Price (as of August 24, 2026, 4:00 p.m. ET): $67.28 USD

Market cap: $136.89 billion (as of August 24, 2026)

Sector / Industry: Health Care / Pharmaceuticals

Index membership: S&P 500